Appointment | December 01, 2021
Sygnature Discovery appoints Louisa Jordison as Chief Financial Officer
She replaces Victoria Tabiner, who is stepping down after 10 years at Sygnature
She replaces Victoria Tabiner, who is stepping down after 10 years at Sygnature
State-of-the-art R&D facility designed to foster collaboration across world-class science ecosystem
The investment will be used to develop affordable Point of Care labs with 70+ tests. Mylab will start deploying systems with its lab partners from Nov 2021
The investment will be used to develop affordable Point of Care labs with 70+ tests. Mylab will start deploying systems with its lab partners from Nov 2021
Research collaboration covers multiple antibody research programs
The company's discovery services support a wide range of global innovator companies from start-ups to large pharma companies, across a diverse set of therapeutic areas including oncology, CNS, antivirals, and inflammation among others
Purchase price of US $ 1.5 billion upfront and up to USD 500 million in success-based milestone payments
This Orphan Drug Designation from the USFDA underlines the urgent medical need to develop a therapy for sickle cell disease
The facility is dedicated to breakthrough innovations in laboratory instruments that detect infectious diseases, cancer, and blood disorders
CSPC will receive an upfront $1.2 billion from AstraZeneca for access to eight programmes, AI molecular design capabilities, and the LiquidGel platform
Subscribe To Our Newsletter & Stay Updated
